Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FREQ Frequency Therapeutics (FREQ) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Frequency Therapeutics alerts: Email Address About Frequency Therapeutics Stock (NASDAQ:FREQ) 30 days 90 days 365 days Advanced Chart Ad InvestorPlace“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.Go here for the full details now. Get Frequency Therapeutics alerts:Sign Up Key Stats Today's Range$0.28▼$0.3250-Day Range$0.22▼$14.9852-Week Range$0.18▼$16.00Volume309,164 shsAverage Volume822,537 shsMarket Capitalization$10.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewFrequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More… “I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (Ad)Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.Go here for the full details now. Receive FREQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FREQ Stock News HeadlinesCurrentBody’s Radio Frequency Wand Delivers Skin-Tightening Tech At HomeSeptember 18 at 6:25 PM | nz.news.yahoo.comMany women experience pain with sex. Is pelvic floor therapy the answer not enough people are talking about?September 17 at 11:53 AM | msn.com“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.September 19, 2024 | InvestorPlace (Ad)How Hyperbaric Oxygen Therapy works?September 17 at 11:53 AM | msn.comTrishula Therapeutics Presents Positive Results from Phase 1 Trial of TTX-030 in First-Line Metastatic Pancreatic Cancer PatientsSeptember 16 at 4:47 PM | finance.yahoo.comKate Winslet touts testosterone replacement therapy. What is that?September 16 at 4:47 PM | msn.comStoke Therapeutics’ STK-001 Shows Sustained Efficacy in Dravet Syndrome, Justifying Buy RatingSeptember 12, 2024 | markets.businessinsider.comStudy shows CAR T-cell therapy's risk of second primary malignancies comparable to other treatmentsSeptember 11, 2024 | msn.comSee More Headlines FREQ Stock Analysis - Frequently Asked Questions How were Frequency Therapeutics' earnings last quarter? Frequency Therapeutics, Inc. (NASDAQ:FREQ) released its earnings results on Monday, November, 15th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.16. When did Frequency Therapeutics IPO? Frequency Therapeutics (FREQ) raised $102 million in an initial public offering on Thursday, October 3rd 2019. The company issued 6,700,000 shares at $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Mizuho Securities was co-manager. What other stocks do shareholders of Frequency Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM) and Atreca (BCEL). Company Calendar Last Earnings11/15/2021Today9/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FREQ CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.67% Return on Assets-61.40% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$14.07 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book0.15Miscellaneous Outstanding Shares36,520,000Free Float30,385,000Market Cap$10.94 million OptionableNot Optionable Beta0.84 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:FREQ) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Frequency Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Frequency Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.